Published in Medical Letter on the CDC and FDA, January 8th, 2006
Baxter will market and sell Hylenex, a proprietary recombinant human hyaluronidase, in the United States.
"We are thrilled that the FDA has approved our first NDA [new drug application] filing," said Jonathan Lim, MD, Halozyme's chairman and CEO. "This is a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.